Literature DB >> 22159057

Propylthiouracil-induced lupus, antiphospholipid syndrome, and stroke in a patient with Graves hyperthyroidism.

Gustavo A Ortiz1, Violet Lagari-Libhaber, Luz Marina Prieto-Sanchez, Alejandro A Rabinstein.   

Abstract

OBJECTIVE: To describe a case of propylthiouracil-induced lupus, complicated with antiphospholipid syndrome and acute ischemic stroke.
DESIGN: Case report.
SETTING: Academic medical center. PATIENT: A 27-year-old man with a diagnosis of Graves disease developed multiple ischemic strokes 2 weeks after starting treatment with propylthiouracil. Thyrotoxicosis and abnormal hypercoagulable and rheumatological profiles were remarkable, with prolonged partial thromboplastin time, elevated anticardiolipin antibody level, and positive antinuclear antibody, lupus anticoagulant, Sjögren antibody, and anti-double-stranded DNA antibody test results, which were more than 8-fold greater than normal values. No clinical manifestations of systemic lupus erythematosus were present. INTERVENTION: Discontinuation of propylthiouracil and treatment with radioactive iodine.
RESULTS: Hyperthyroidism resolved and anti-double-stranded DNA antibodies returned to normal levels. Eventually, antiphospholipid syndrome was diagnosed. He was treated with oral anticoagulation and remained asymptomatic for 1 year of follow-up.
CONCLUSION: In this young man with Graves hyperthyroidism, treatment with propylthiouracil was associated with transient autoimmune reactions suggestive of drug-induced lupus, antiphospholipid syndrome, and acute ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22159057     DOI: 10.1001/archneurol.2011.838

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  1 in total

1.  An extensive posterior circulation infarction secondary to primary hyperthyroidism accompanied with superior mesenteric artery syndrome: A case report and description of patho-physiological association.

Authors:  Hong-Kai Wang; Wen-Hsuan Huang; Ko-Ting Chen
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.